 |
|
|
| |
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF FALDAPREVIR IN COMBINATION WITH PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION
|
| |
| |
Download the PDF here
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
IM Jacobson1, T Asselah2, P Ferenci3, GR Foster4, DM Jensen5, F Negro6, P Mantry7, D Wright8, X Forns9, J Garcia-Samaniego10, C Oliveira11, A Carvalho12, D Forton13, K Agarwal14, K Arastéh15, C Cooper16, W Ghesquiere17, J-F Dufour18, Y Sakai19, Y Tanaka20, JO Stern21, N Sha21, WO Boecher22, G Steinmann22, AM Quinson21, on behalf of the STARTVerso3 Study Group
1New York Presbyterian Weill Cornell Medical Center, New York, NY, USA; 2Hôpital Beaujon, APHP, University Paris-Diderot and Inserm CRB3, Clichy, France; 3Medical University of Vienna, Vienna, Austria; 4Queen Mary, University of London, London, UK; 5University of Chicago Medicine, Chicago, IL, USA; 6University Hospital, Geneva, Switzerland; 7The Liver Institute at Methodist Dallas Medical Center Dallas, TX, USA; 8Central Texas Clinical Research, Austin, TX, USA; 9Liver Unit, Hospital Clinic. IDIBAPS and CIBEREHD, Barcelona, Spain; 10Hospital Carlos III, CIBERehd, Unidad de Hepatología, Madrid, Spain; 11Hospital Infante D. Pedro, Aveiro, Portugal;12Hospitais da Universidade De Coimbra, Coimbra, Portugal; 13St George's Hospital, London, UK; 14King's College Hospital, London, UK; 15EPIMED, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 16Ottawa Hospital Research Institute, Ottawa ON, Canada; 17University of British Columbia, Victoria BC, Canada; 18University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 19Hyogo College of Medicine Hospital, Hyogo, Japan; 20Nagoya City University Hospital, Aichi, Japan; 21Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 22Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, German
|
| |
|
|
|
|
|
